These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 26667139)
1. Insulin-like growth factor 1 receptor signaling via Akt: a general therapeutic target in neurocutaneous melanocytosis? Patel J; Salgado CM; Múgica MR; Basu D Neuro Oncol; 2016 Jan; 18(1):142-3. PubMed ID: 26667139 [No Abstract] [Full Text] [Related]
2. Response to "Insulin-like growth factor 1 receptor signaling via Akt: a general therapeutic target in neurocutaneous melanocytosis?". Ruan Y; Narendran A Neuro Oncol; 2016 Jan; 18(1):143-4. PubMed ID: 26667140 [No Abstract] [Full Text] [Related]
3. Druggable targets in pediatric neurocutaneous melanocytosis: Molecular and drug sensitivity studies in xenograft and ex vivo tumor cell culture to identify agents for therapy. Ruan Y; Kovalchuk A; Jayanthan A; Lun X; Nagashima Y; Kovalchuk O; Wright JR; Pinto A; Kirton A; Anderson R; Narendran A Neuro Oncol; 2015 Jun; 17(6):822-31. PubMed ID: 25395461 [TBL] [Abstract][Full Text] [Related]
4. Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor. Küsters-Vandevelde HV; Willemsen AE; Groenen PJ; Küsters B; Lammens M; Wesseling P; Djafarihamedani M; Rijntjes J; Delye H; Willemsen MA; van Herpen CM; Blokx WA Acta Neuropathol Commun; 2014 Apr; 2():41. PubMed ID: 24713450 [TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical detection of the c-met proto-oncogene product in the congenital melanocytic nevus of an infant with neurocutaneous melanosis. Takayama H; Nagashima Y; Hara M; Takagi H; Mori M; Merlino G; Nakazato Y J Am Acad Dermatol; 2001 Mar; 44(3):538-40. PubMed ID: 11209133 [TBL] [Abstract][Full Text] [Related]
6. Common presentation in an uncommon disease: case report of a patient with primary diffuse leptomeningeal melanocytosis. Dechaphunkul A; Kayasut K; Oearsakul T; Koonlaboon K; Sunpaweravong P J Clin Oncol; 2011 Nov; 29(33):e816-8. PubMed ID: 22025160 [No Abstract] [Full Text] [Related]
7. Copy number abnormalities in new or progressive 'neurocutaneous melanosis' confirm it to be primary CNS melanoma. Kinsler VA; Polubothu S; Calonje JE; Chong WK; Thompson D; Jacques TS; Morrogh D Acta Neuropathol; 2017 Feb; 133(2):329-331. PubMed ID: 27933403 [No Abstract] [Full Text] [Related]
8. Copy number variations as potential diagnostic and prognostic markers for CNS melanocytic neoplasms in neurocutaneous melanosis. van Engen-van Grunsven AC; Rabold K; Küsters-Vandevelde HV; Rijntjes J; Djafarihamedani M; Hehir-Kwa JY; Küsters B; Willemsen MA; van der Burgt I; Wesseling P; Blokx WA; Groenen PJ Acta Neuropathol; 2017 Feb; 133(2):333-335. PubMed ID: 27988846 [No Abstract] [Full Text] [Related]
9. Rapid response to therapy of neurocutaneous melanosis with leptomeningeal melanoma. Subbiah V; Wolff JE Pediatr Blood Cancer; 2010 Jan; 54(1):180-1. PubMed ID: 19722276 [No Abstract] [Full Text] [Related]
10. [Neurocutaneous melanosis and multiple congenital melanocytic naevi are associated with post-zygotic N-ras mutations]. Dereure O Ann Dermatol Venereol; 2014 Apr; 141(4):314-5. PubMed ID: 24703650 [No Abstract] [Full Text] [Related]
11. CSF cytology diagnosis of NRAS-mutated primary leptomeningeal melanomatosis with neurocutaneous melanosis. Kolin DL; Geddie WR; Ko HM Cytopathology; 2017 Jun; 28(3):235-238. PubMed ID: 27696542 [No Abstract] [Full Text] [Related]
13. Atypical dermal melanocytosis: a diagnostic clue in constitutional mismatch repair deficiency syndrome. Polubothu S; Scott RH; Vabres P; Kinsler VA Br J Dermatol; 2017 Nov; 177(5):e185-e186. PubMed ID: 28369758 [No Abstract] [Full Text] [Related]
14. Resveratrol-induced thrombocytopenia: Inadvertent side-effect of a commonly used antioxidant. Kumaran MS; Dabas G; Kapadia AB; Parsad D Dermatol Ther; 2018 Jan; 31(1):. PubMed ID: 29193562 [No Abstract] [Full Text] [Related]
15. Severe hydrocephalus caused by diffuse leptomeningeal and neurocutaneous melanocytosis of antenatal onset: a clinical, pathologic, and molecular study of 2 cases. Uguen A; Laurent C; Samaison L; Boisselier B; Talagas M; Costa S; Aziza J; Mokhtari K; Le Maréchal C; Marcorelles P Hum Pathol; 2015 Aug; 46(8):1189-96. PubMed ID: 26037215 [TBL] [Abstract][Full Text] [Related]
16. Novel Finding of Copy Number Gains in GNAS and Loss of 10q in a Child With Malignant Transformation of Neurocutaneous Melanosis Syndrome. Peterson C; Toll SA; Kolb B; Poulik JM; Reyes-Mugica M; Sood S; Haridas A; Wang ZJ; Marupudi NI JCO Precis Oncol; 2021 Nov; 5():33-38. PubMed ID: 34994589 [No Abstract] [Full Text] [Related]
18. Amplification of mutated NRAS leading to congenital melanoma in neurocutaneous melanocytosis. Salgado CM; Basu D; Nikiforova M; Hamilton RL; Gehris R; Jakacki R; Panigrahy A; Yatsenko S; Reyes-Múgica M Melanoma Res; 2015 Oct; 25(5):453-60. PubMed ID: 26266759 [TBL] [Abstract][Full Text] [Related]
19. Evidence of neural crest cell origin of a DICER1 mutant CNS sarcoma in a child with DICER1 syndrome and NRAS-mutant neurocutaneous melanosis. Schweizer L; Hartmann W; Koch A; Nunninger M; Thomale UW; Pennacchietti V; Tietze A; Horn D; Pajtler KW; Hirsch S; Wieland I; Deubzer H; Rossi R; Driever PH; von Hoff K; von Zezschwitz B Neuropathol Appl Neurobiol; 2022 Oct; 48(6):e12830. PubMed ID: 35728810 [No Abstract] [Full Text] [Related]
20. Melanoma of the central nervous system based on neurocutaneous melanocytosis in childhood: A rare but fatal condition. Abele M; Forchhammer S; Eigentler TK; Popescu A; Maschke L; Lohse J; Lehrnbecher T; Behnisch W; Groll AH; Jakob M; Bernbeck B; Brecht IB; Schneider DT Pediatr Blood Cancer; 2024 Apr; 71(4):e30859. PubMed ID: 38225622 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]